Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Renee Al-Sarraf x
  • Refine by Access: All Content x
Clear All Modify Search

Abstract

Objective—To determine clinical activity and toxic effects of lomustine when used to treat cats with mast cell tumors (MCTs).

Design—Retrospective case series.

Animals—38 cats with measurable, histologically or cytologically confirmed MCTs treated with lomustine at a dosage ≥ 50 mg/m2.

Procedures—Medical records were reviewed to determine response to treatment and evidence of drug toxicoses. The Kaplan-Meier method was used to estimate remission duration.

Results—26 cats had cutaneous MCTs, 7 had MCTs of the mesenteric lymph nodes, 2 had gastrointestinal tract MCTs, 2 had hepatic MCTs, and 1 had MCTs involving multiple organs. Targeted lomustine dosage was 50 mg/m2 in 22 cats and 60 mg/m2 in 16 cats. Median administered dosage of lomustine was 56 mg/m2 (range, 48 to 65 mg/m2), and median number of doses administered was 2 (range, 1 to 12). Seven cats had a complete response and 12 had a partial response, for an overall response rate of 50%. Median response duration was 168 days (range, 25 to 727 days). The most common toxicoses were neutropenia and thrombocytopenia.

Conclusions and Clinical Relevance—Results suggested that lomustine had activity against MCTs in cats and was well tolerated. Further, findings suggested that treatment with lomustine should be considered for cats with MCTs for which local treatment is not an option.

Restricted access
in Journal of the American Veterinary Medical Association

Abstract

Objective—To evaluate response rate and duration of malignant melanomas in dogs treated with carboplatin.

Design—Retrospective study.

Animals—27 client-owned dogs with spontaneously occurring measurable malignant melanomas.

Procedure—Records of dogs with melanomas treated with carboplatin from October 1989 to June 2000 were reviewed. Carboplatin was administered IV at doses of 300 or 350 mg/m2 of body surface area. Response to treatment and evidence of drug toxicity were determined.

Result—Response to treatment could be evaluated in 25 dogs. Of those, overall response rate was 28%. One dog had a complete response, 6 (24%) dogs had a partial response (> 50% reduction in tumor burden). Median duration of partial response was 165 days. Eighteen dogs had stable disease (n = 9; 36%) or progressive disease (9; 36%). Response to treatment was significantly associated with carboplatin dose on a milligram per kilogram basis (15.1 mg/kg [6.9 mg/lb] of body weight vs 12.6 mg/kg [5.7 mg/lb]). Evidence of gastrointestinal toxicosis could be assessed in 27 dogs. Mean body weight of 5 dogs that developed gastrointestinal toxicosis was significantly less than that of 22 dogs without gastrointestinal toxicosis (9.9 kg [21.8 lb] vs 19.3 kg [42.5 lb]).

Conclusions and Clinical Relevance—Carboplatin had activity against macroscopic spontaneously occurring malignant melanomas in dogs and should be considered as an adjunctive treatment for microscopic local or metastatic tumors. Gastrointestinal toxicosis was associated with body weight. Because small dogs are more likely to have adverse gastrointestinal effects, gastrointestinal protectants should be considered for these patients. (J Am Vet Med Assoc 2001;218:1444–1448)

Restricted access
in Journal of the American Veterinary Medical Association